Patents by Inventor Yasufumi MURAKAMI

Yasufumi MURAKAMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10893216
    Abstract: An electronic apparatus includes an image acquisition unit configured to obtain a wide range image, an information acquisition unit configured to obtain attribute information including orientation information, and a control unit configured to control selection of any one of a plurality of processes based on a condition to display the wide range image, the plurality of processes including at least two of first to fourth processes, the first process providing a display in which a zenith and a yaw angle is corrected based on the orientation information, the second process providing a display in which the zenith is corrected based on the orientation information, the third process providing a display in which the yaw angle is corrected based on the orientation information, the fourth process providing a display in which neither the zenith nor the yaw angle of the wide range image is corrected.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 12, 2021
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yasufumi Oyama, Shin Murakami
  • Patent number: 10807987
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 20, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuya Oguro, Shigemitsu Matsumoto, Takeshi Wakabayashi, Norihito Tokunaga, Taku Kamei, Mitsuhiro Ito, Satoshi Mikami, Masaki Seto, Shinji Morimoto, Shinji Nakamura, Sachie Takashima, Masataka Murakami, Masaki Daini, Makoto Kamata, Minoru Nakamura, Yasufumi Wada, Hiroyuki Kakei, Kazuaki Takami, Taisuke Tawaraishi, Jumpei Aida, Kouichi Iwanaga, Satoshi Yamamoto
  • Publication number: 20200165330
    Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.
    Type: Application
    Filed: January 5, 2017
    Publication date: May 28, 2020
    Applicants: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasufumi MURAKAMI, Shigeki MUKOUBATA, Hirotada AKIYAMA, Koji KONOMI
  • Publication number: 20190322732
    Abstract: An object of the present invention is to provide an antibody against VEGF that inhibits binding of a vascular endothelial growth factor (VEGF) to neuropilin-1 (NRP1). The present invention provides an antibody against VEGF that inhibits binding of VEGF to NRP1.
    Type: Application
    Filed: January 5, 2017
    Publication date: October 24, 2019
    Applicants: ORDER-MADE MEDICAL RESEARCH INC., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Yasufumi MURAKAMI, Hiroyuki SATOFUKA, Shigeki MUKOUBATA, Hirotada AKIYAMA, Tatsuji KUROSE, Sae AKAO
  • Publication number: 20190300536
    Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuya OGURO, Shigemitsu MATSUMOTO, Takeshi WAKABAYASHI, Norihito TOKUNAGA, Taku KAMEI, Mitsuhiro ITO, Satoshi MIKAMI, Masaki SETO, Shinji MORIMOTO, Shinji NAKAMURA, Sachie TAKASHIMA, Masataka MURAKAMI, Masaki DAINI, Makoto KAMATA, Minoru NAKAMURA, Yasufumi WADA, Hiroyuki KAKEI, Kazuaki TAKAMI, Taisuke TAWARAISHI, Jumpei AIDA, Kouichi IWANAGA, Satoshi YAMAMOTO
  • Publication number: 20190208141
    Abstract: An electronic apparatus includes an image acquisition unit configured to obtain a wide range image, an information acquisition unit configured to obtain attribute information including orientation information, and a control unit configured to control selection of any one of a plurality of processes based on a condition to display the wide range image, the plurality of processes including at least two of first to fourth processes, the first process providing a display in which a zenith and a yaw angle is corrected based on the orientation information, the second process providing a display in which the zenith is corrected based on the orientation information, the third process providing a display in which the yaw angle is corrected based on the orientation information, the fourth process providing a display in which neither the zenith nor the yaw angle of the wide range image is corrected.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 4, 2019
    Inventors: Yasufumi Oyama, Shin Murakami
  • Patent number: 10214584
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 26, 2019
    Assignee: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki Satofuka, Kensuke Ohse, Shigeki Mukobata, Hirotada Akiyama, Masaya Ohtsu, Yoko Okabe, Yasufumi Murakami
  • Publication number: 20160333092
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Applicant: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki SATOFUKA, Kensuke OHSE, Shigeki MUKOBATA, Hirotada AKIYAMA, Masaya OHTSU, Yoko OKABE, Yasufumi MURAKAMI
  • Publication number: 20160116478
    Abstract: The object of the present invention is to provide a reagent for detection or diagnosis of cancer. The present invention provides a reagent for detection or diagnosis of cancer, which comprises a monoclonal antibody against LGR6 or a fragment of the antibody.
    Type: Application
    Filed: May 29, 2014
    Publication date: April 28, 2016
    Applicant: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki SATOFUKA, Yasufumi MURAKAMI